Natural history in spinal muscular atrophy Type I in Taiwanese population: A longitudinal study.

Brain Dev

Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Departments of Pediatrics and Laboratory Medicine, and Translational Research Center of Neuromuscular Diseases, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; College of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan. Electronic address:

Published: January 2021

AI Article Synopsis

  • Spinal muscular atrophy (SMA) Type I is linked to a defect in the SMN1 gene, and a study in Taiwan tracked the disease's progression in untreated patients over 36 years (1979-2015).* -
  • Researchers collected data on patient demographics, genetics, treatment types, and clinical outcomes, finding a significant difference in survival probabilities between patients born in different time periods and based on the number of SMN2 gene copies.* -
  • The study highlighted the short life expectancy for SMA Type I patients in Taiwan before treatment options were available, while also showing that supportive care like tracheostomy and gastrostomy can lead to better survival outcomes.*

Article Abstract

Introduction: Spinal muscular atrophy (SMA) is caused by a defect in the survival motor neuron 1 (SMN1) gene. The Cooperative Study of the natural history of SMA Type I in Taiwan is a retrospective, longitudinal, observational study that helps in further understanding SMA disease progression in patients who have not received disease-modifying therapeutic interventions.

Methods: Case report forms were used to collect demographics; genetic confirmation; SMN2 copy number; treatment patterns; and clinical outcomes including ventilator use, endotracheal tube intubation, tracheostomy, gastrostomy, complications, and survival.

Results: A total of 111 patients with SMA Type I were identified over the study period (1979-2015). Mean (median) age of onset and age at confirmed diagnosis were 1.3 (0.8) and 4.9 (4.4) months, respectively. SMN1 deletion/mutation was documented in 70 patients and SMN2 copy number in 32 (2 copies, n = 20; 3 copies, n = 12). At 240 months, survival probability for patients born during 1995-2015 versus 1979-1994 was significantly longer (p = 0.0057). Patients with 3 SMN2 copies showed substantially longer 240-month survival versus patients with 2 SMN2 copies. Over the 36-year period, mean (median) age at death was 31.9 (8.8) months. As of December 2015, 95 patients had died, 13 were alive, and 3 were lost to follow-up. The use of supportive measures (tracheostomy and gastrostomy) was associated with improved survival.

Conclusions: These data describe the short survival of patients with SMA Type I in Taiwan in the pretreatment era, emphasizing the positive impact of supportive measures on survival.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.braindev.2020.07.012DOI Listing

Publication Analysis

Top Keywords

sma type
12
patients smn2
12
natural history
8
spinal muscular
8
muscular atrophy
8
type taiwan
8
patients
8
smn2 copy
8
copy number
8
tracheostomy gastrostomy
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!